Q-omics provides the consensus-scored PCDH11X profile across patient tissues and cancer cell-line models. PCDH11X expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PCDH11X is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, PCDH11X RNA expression shows 12,593 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where PCDH11X shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH11X — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH11X survival associations across molecular data types. PCDH11X RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH11X RNA expression–survival associations across cancer types. High PCDH11X expression shows unfavorable associations in UVM, UCEC, THCA and KIRP, but favorable associations in LGG and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PCDH11X RNA expression.
This table summarizes PCDH11X tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PCDH11X. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH11X shows lower tumor expression in COAD, THCA, KICH, BRCA, LUAD and KIRP. The COAD box plot shows higher PCDH11X RNA expression in normal versus tumor tissue (log2 FC = −0.035, t-test p < 0.001).
This table shows molecular features associated with PCDH11X in patient tissues and cancer cell lines. In patient samples, PCDH11X shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDH11X RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
